佛慈制藥(002644.SZ)擬1.03億元向控股股東轉讓2宗工業地
格隆匯12月13日丨佛慈制藥(002644.SZ)公佈，為貫徹落實省、市政府對佛慈醫藥產業做優做強、重組整合的工作要求，有效盤活公司存量資產，促使公司("甲方")聚焦製藥主業，降低公司資金壓力、融資成本和涉税風險，公司擬將位於蘭州市安寧區代家莊2號和蘭州市安寧區莫高大道中海廣場南側兩處土地按照評估確認的市場公允價值加相關前期費用的作價原則，以約1.03億元的價格轉讓給控股股東蘭州佛慈醫藥產業發展集團有限公司(“佛慈集團”，乙方)。
佛慈集團持有公司61.63%的股份，為公司控股股東，根據《深圳證券交易所股票上市規則》《深圳證券交易所中小板上市公司規範運作指引》等相關規定，此次交易構成關聯交易。
地塊一位於蘭州市安寧區代家莊2號，面積為23723.8㎡(約35.59畝)，土地用途為工業用地；地塊二位於蘭州市安寧區莫高大道中海廣場南側，面積為45642.10㎡(約68.46畝)，土地用途為工業用地，土地四至以宗地圖為準。
上述土地原屬於甲方生產經營用地，後因蘭州市城市搬遷政策要求甲方生產 經營場地搬遷後上述土地閒置。甲方為盤活資產、提高資產使用效益，經履行相 關程序後決定轉讓，乙方在受讓前已獲知上述宗地的全部情況並願意受讓。
因公司目前主營業務為中成藥及大健康產品的研發、製造和銷售，若自主開發商業住宅項目，將導致公司主營業務發生變更，無法享受西部大開發相關税收優惠政策；同時，當前房地產行業融資政策日趨收緊，商業地產項目開發將加劇公司資金壓力和融資成本，加大公司經營風險。經審慎研究評估，公司擬將上述兩處土地轉讓給公司控股股東佛慈集團。
此次轉讓土地使用權是根據公司發展戰略的需要，有利於盤活公司存量資產，實現公司資源的有效配置和重組整合，促使公司聚焦製藥主業，降低公司後續資金壓力和涉税風險，符合公司及全體股東的利益。
此次交易需提交公司股東大會審議批准，後續還需辦理產權過户等相關手續，預計對公司本期利潤不會產生影響。若此次交易順利完成，預計將增加公司後期利潤總額約7858.60萬元(不考慮税收影響)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
